Bayer CEO speaks out on NICE's rejecton of anticancer drug
This article was originally published in Scrip
Executive Summary
Arthur Higgins, CEO of Bayer Healthcare, has criticised a recent preliminary decision by the UK's National Institute for health and Clinical Excellence (NICE), which rejected his firm's anticancer product Nexavar (sorafenib) for use on the national health service (NHS).